Alexander Mark  Schobel net worth and biography

Alexander Schobel Biography and Net Worth

Mark Schobel was appointed as Chief Innovation & Technology Officer of Aquestive in 2014 after serving as the Company’s Chief Executive Officer, Co-President and a member of its Board of Directors since November 2005.  From March 2001 to November 2005, he was the Global Head of New Technology and Product Innovation for the Consumer Health Business Unit at Novartis where he pioneered thin film delivery of systemic drugs.  Prior to Novartis, Mr. Schobel held various general management positions with Reed & Carnrick Pharmaceuticals, Warner-Lambert, and Pharmaceutical Formulations Inc.

What is Alexander Mark Schobel's net worth?

The estimated net worth of Alexander Mark Schobel is at least $6.34 million as of March 15th, 2024. Schobel owns 984,476 shares of Aquestive Therapeutics stock worth more than $6,340,025 as of December 5th. This net worth estimate does not reflect any other investments that Schobel may own. Additionally, Schobel receives a salary of $672,690.00 as Insider at Aquestive Therapeutics. Learn More about Alexander Mark Schobel's net worth.

How old is Alexander Mark Schobel?

Schobel is currently 65 years old. There are 7 older executives and no younger executives at Aquestive Therapeutics. The oldest executive at Aquestive Therapeutics is Ms. Lori J. Braender BSBA, Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary, who is 68 years old. Learn More on Alexander Mark Schobel's age.

What is Alexander Mark Schobel's salary?

As the Insider of Aquestive Therapeutics, Inc., Schobel earns $672,690.00 per year. There are 2 executives that earn more than Schobel. The highest earning executive at Aquestive Therapeutics is Mr. Daniel Barber, CEO, President & Director, who commands a salary of $1,060,000.00 per year. Learn More on Alexander Mark Schobel's salary.

How do I contact Alexander Mark Schobel?

The corporate mailing address for Schobel and other Aquestive Therapeutics executives is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. Aquestive Therapeutics can also be reached via phone at (908) 941-1900 and via email at [email protected]. Learn More on Alexander Mark Schobel's contact information.

Has Alexander Mark Schobel been buying or selling shares of Aquestive Therapeutics?

Alexander Mark Schobel has not been actively trading shares of Aquestive Therapeutics in the last ninety days. Most recently, Alexander Mark Schobel sold 50,000 shares of the business's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $6.00, for a transaction totalling $300,000.00. Following the completion of the sale, the insider now directly owns 984,476 shares of the company's stock, valued at $5,906,856. Learn More on Alexander Mark Schobel's trading history.

Who are Aquestive Therapeutics' active insiders?

Aquestive Therapeutics' insider roster includes Cassie Jung (COO), and Alexander Schobel (Insider). Learn More on Aquestive Therapeutics' active insiders.

Are insiders buying or selling shares of Aquestive Therapeutics?

In the last year, insiders at the sold shares 8 times. They sold a total of 276,770 shares worth more than $1,692,203.04. The most recent insider tranaction occured on October, 15th when COO Cassie Jung sold 67,575 shares worth more than $473,700.75. Insiders at Aquestive Therapeutics own 8.4% of the company. Learn More about insider trades at Aquestive Therapeutics.

Information on this page was last updated on 10/15/2025.

Alexander Mark Schobel Insider Trading History at Aquestive Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2024Sell50,000$6.00$300,000.00984,476View SEC Filing Icon  
3/8/2024Sell25,000$5.19$129,750.001,040,371View SEC Filing Icon  
6/8/2022Buy45,871$0.96$44,036.16882,871View SEC Filing Icon  
2/10/2021Sell23,460$6.75$158,355.00860,460View SEC Filing Icon  
2/8/2021Sell40,792$6.50$265,148.00860,460View SEC Filing Icon  
4/29/2020Sell40,000$4.50$180,000.001,022,113View SEC Filing Icon  
4/27/2020Sell40,000$4.00$160,000.00982,113View SEC Filing Icon  
4/14/2020Sell40,000$3.70$148,000.00982,113View SEC Filing Icon  
12/6/2018Buy2,000$8.69$17,380.00View SEC Filing Icon  
11/21/2018Buy1,000$10.25$10,250.00View SEC Filing Icon  
See Full Table

Alexander Mark Schobel Buying and Selling Activity at Aquestive Therapeutics

This chart shows Alexander Mark Schobel's buying and selling at Aquestive Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aquestive Therapeutics Company Overview

Aquestive Therapeutics logo
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Read More

Today's Range

Now: $6.44
Low: $6.13
High: $6.55

50 Day Range

MA: $6.25
Low: $5.30
High: $7.49

2 Week Range

Now: $6.44
Low: $2.12
High: $7.55

Volume

2,274,110 shs

Average Volume

2,709,055 shs

Market Capitalization

$785.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59